In the present trial, Tiotropium was superior in all respects and is very effective in bronchial asthma patients. The degree of bronchodilation in this trial is effective. There are very few trials available to prove the efficacy of tiotropium bromide in bronchial asthma patients. But in the present study, it is reported that tiotropium is also effective in mild intermittent and mild persistent asthma patients in both the aspects that is clinically as well as spirometric tests. Therefore, Tiotropium has the potential to provide superior bronchodilatation with once daily dosing. Present study supports the findings observed in the previous studies. No adverse effects were reported in any of the treatment groups, using tiotropium except in very few cases i.e.